NCT03018028 - Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes | Biotech Hunter

Enrollment

243

Participants

Timeline

Start Date

January 10, 2017

Primary Completion Date

January 9, 2018

Study Completion Date

August 15, 2018

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

Semaglutide

Oral administration once daily

DRUG

Placebo

Oral administration once daily

DRUG

Liraglutide

Subcutaneous (s.c., under the skin) injection once daily

Trial Locations (16)

010-8543

Novo Nordisk Investigational Site, Akita-shi, Akita

116-0012

Novo Nordisk Investigational Site, Arakawa-ku, Tokyo

243-0432

Novo Nordisk Investigational Site, Ebina-shi, Kanagawa

373-0036

Novo Nordisk Investigational Site, Gunma

232-0064

Novo Nordisk Investigational Site, Kanagawa

108-0075

Novo Nordisk Investigational Site, Minato-ku, Tokyo

311 0113

Novo Nordisk Investigational Site, Naka

553-0003

Novo Nordisk Investigational Site, Osaka-shi, Osaka

144-0051

Novo Nordisk Investigational Site, Ota-ku, Tokyo

849-0937

Novo Nordisk Investigational Site, Saga-shi, Saga

980-8574

Novo Nordisk Investigational Site, Sendai-shi, Miyagi

565-0853

Novo Nordisk Investigational Site, Suita-shi, Osaka

103-0027

Novo Nordisk Investigational Site, Tokyo

103-0028

Novo Nordisk Investigational Site, Tokyo

104-0031

Novo Nordisk Investigational Site, Tokyo

160-0008

Novo Nordisk Investigational Site, Tokyo